hVIVO (LON:HVO) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?

hVIVO plc (LON:HVO)’s share price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 5.97 and traded as high as GBX 6. hVIVO shares last traded at GBX 5.83, with a volume of 2,080,140 shares trading hands.

Analysts Set New Price Targets

Separately, Peel Hunt reiterated an “add” rating and set a GBX 10 price objective on shares of hVIVO in a report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, hVIVO has an average rating of “Buy” and an average price target of GBX 17.50.

hVIVO Stock Up 4.1%

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock’s 50 day simple moving average is GBX 5.97 and its 200 day simple moving average is GBX 7.70. The firm has a market cap of £42.91 million, a P/E ratio of 8.11 and a beta of 0.97.

Insider Transactions at hVIVO

In related news, insider Stephen Pinkerton acquired 520,000 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was purchased at an average cost of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan acquired 3,310,405 shares of the stock in a transaction dated Monday, December 15th. The stock was bought at an average cost of GBX 6 per share, with a total value of £198,624.30. Corporate insiders own 4.43% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.